Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
D000907:Antibodies, Bacterial / Q000032:analysis; D016667:Bacterial Capsules / Q000276:immunology; D002353:Carrier State / Q000517:prevention & control*; D017322:Clinical Trials, Phase II as Topic; D016001:Confidence Intervals; D022422:Diphtheria-Tetanus Vaccine / Q000008:administration & dosage*; D005260:Female; D005387:Finland; D006801:Humans; D007109:Immunity / Q000502:physiology; D007117:Immunization, Secondary; D007223:Infant; D007557:Israel; D008297:Male; D011008:Pneumococcal Infections / Q000276:immunology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage*; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage* / Q000276:immunology; D011336:Probability; D012698:Serologic Tests; D013296:Streptococcus pneumoniae / Q000276:immunology; D014611:Vaccination / Q000379:methods*; D018074:Vaccines, Conjugate / Q000008:administration & dosage
D000907:Antibodies, Bacterial; D022422:Diphtheria-Tetanus Vaccine; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate